Last reviewed · How we verify

Horizant (GABAPENTIN ENACARBIL)

Azurity · FDA-approved approved Small molecule Under review Quality 10/100

Horizant (generic name: GABAPENTIN ENACARBIL) is a Anti-epileptic Agent Small molecule drug developed by Azurity. It is currently FDA-approved (first approved 2011) for Postherpetic neuralgia, Restless legs.

Horizant works by binding to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, reducing the release of excitatory neurotransmitters and alleviating pain.

Horizant, also known as gabapentin enacarbil, is a small molecule that modulates voltage-gated calcium channels. It has been studied in various clinical trials for conditions such as adolescent idiopathic scoliosis, treatment-resistant depression, and blood pressure, among others.

At a glance

Generic nameGABAPENTIN ENACARBIL
SponsorAzurity
Drug classAnti-epileptic Agent
TargetVoltage-dependent calcium channel subunit alpha-2/delta-1
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval2011

Mechanism of action

Gabapentin enacarbil is prodrug of gabapentin and, accordingly, its therapeutic effects in RLS and PHN are attributable to gabapentin.The precise mechanism by which gabapentin is efficacious in RLS and PHN is unknown.The mechanism of action by which gabapentin is efficacious in PHN is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g., spinal nerve ligation models, spinal cord injury model, acute herpes zoster infection model). Gabapentin also decreases pain-related responses after peripheral inflammation (carrageenan footpad test, late phase of formalin test), but does not alter immediate pain-related behaviors (rat tail flick test, formalin footpad acute phase). The relevance of these models to human pain is n

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Horizant

What is Horizant?

Horizant (GABAPENTIN ENACARBIL) is a Anti-epileptic Agent drug developed by Azurity, indicated for Postherpetic neuralgia, Restless legs.

How does Horizant work?

Horizant works by binding to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, reducing the release of excitatory neurotransmitters and alleviating pain.

What is Horizant used for?

Horizant is indicated for Postherpetic neuralgia, Restless legs.

Who makes Horizant?

Horizant is developed and marketed by Azurity (see full Azurity pipeline at /company/azurity).

What is the generic name of Horizant?

GABAPENTIN ENACARBIL is the generic (nonproprietary) name of Horizant.

What drug class is Horizant in?

Horizant belongs to the Anti-epileptic Agent class. See all Anti-epileptic Agent drugs at /class/anti-epileptic-agent.

When was Horizant approved?

Horizant was first approved on 2011.

What development phase is Horizant in?

Horizant is FDA-approved (marketed).

What are the side effects of Horizant?

Common side effects of Horizant include Somnolence/sedation, Dizziness, Headache, Nausea, Fatigue, Irritability.

What does Horizant target?

Horizant targets Voltage-dependent calcium channel subunit alpha-2/delta-1 and is a Anti-epileptic Agent.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing